|SSR240612 is a potent and selective non-peptide bradykinin B1 receptor antagonist with Kis of 0.48 nM and 0.73 nM for B1 kinin receptors of human fibroblast MRC5 and HEK cells expressing human B1 receptors, 481 nM and 358 nM for B2 receptors of guinea pig ileum membranes and CHO cells expressing human B1 receptor, respectively.
|Labradimil, also known as RMP 7, is a bradykinin B2 receptor agonist potentially for the treatment of brain cancer. RMP-7) increases the permeability of human brain microvascular endothelial cell monolayers. RMP-7 enhances delivery of hydrophilic chemotherapeutics and increases survival in rats with metastatic tumors in the brain. RMP-7 increases carboplatin levels in brain tumors after pretreatment with dexamethasone.
|Icatibant is a selective and specific antagonist of bradykinin B2 receptor with IC50 and Ki of 1.07 nM and 0.798 nM respectively.
|Icatibant acetate (HOE-140 acetate) is a potent and specific peptide antagonist of bradykinin B2 receptor with IC50 and Ki of 1.07 nM and 0.798 nM respectively.
|FR167344 free base is an orally active, nonpeptide bradykinin receptor B2 antagonist. FR167344 free base shows a high affinity binding to the B2 receptor with an IC50value of 65 nM and no binding affinity for the B1 receptor.
|ELN-441958 is a potent, neutral antagonist of B1 receptor, inhibits the binding of the B1 agonist ligand [3H]DAKD to IMR-90 cells with Ki of 0.26 nM.
|Bradykinin 2-9, an amino-truncated bradykinin peptide, is a metabolite of bradykinin with no detectable contractile activity. It can inhibit ACE and potentiate BK.